# Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

> **NCT01423058** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 61 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera
- Post-Essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Momelotinib

## Key facts

- **NCT ID:** NCT01423058
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423058, "Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01423058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*